Ignite Creation Date:
2025-12-24 @ 4:47 PM
Ignite Modification Date:
2026-04-23 @ 3:53 AM
Study NCT ID:
NCT02310750
Status:
COMPLETED
Last Update Posted:
2017-03-08
First Post:
2014-11-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000630838', 'term': 'PF-06700841'}, {'id': 'D013535', 'term': 'Suspensions'}], 'ancestors': [{'id': 'D003102', 'term': 'Colloids'}, {'id': 'D045424', 'term': 'Complex Mixtures'}, {'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquires@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 13, 'otherNumAffected': 2, 'seriousNumAtRisk': 13, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.', 'otherNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.', 'otherNumAtRisk': 2, 'otherNumAffected': 1, 'seriousNumAtRisk': 2, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.', 'otherNumAtRisk': 9, 'otherNumAffected': 5, 'seriousNumAtRisk': 9, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 7, 'otherNumAffected': 1, 'seriousNumAtRisk': 7, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 6, 'otherNumAffected': 0, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.', 'otherNumAtRisk': 5, 'otherNumAffected': 3, 'seriousNumAtRisk': 5, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.', 'otherNumAtRisk': 4, 'otherNumAffected': 2, 'seriousNumAtRisk': 4, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 8, 'otherNumAffected': 3, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.', 'otherNumAtRisk': 6, 'otherNumAffected': 3, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG012', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.', 'otherNumAtRisk': 5, 'otherNumAffected': 5, 'seriousNumAtRisk': 5, 'seriousNumAffected': 0}, {'id': 'EG013', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.', 'otherNumAtRisk': 8, 'otherNumAffected': 2, 'seriousNumAtRisk': 8, 'seriousNumAffected': 0}, {'id': 'EG014', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.', 'otherNumAtRisk': 6, 'otherNumAffected': 5, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG015', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.', 'otherNumAtRisk': 14, 'otherNumAffected': 11, 'seriousNumAtRisk': 14, 'seriousNumAffected': 0}, {'id': 'EG016', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.', 'otherNumAtRisk': 7, 'otherNumAffected': 6, 'seriousNumAtRisk': 7, 'seriousNumAffected': 0}, {'id': 'EG017', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.', 'otherNumAtRisk': 12, 'otherNumAffected': 1, 'seriousNumAtRisk': 12, 'seriousNumAffected': 0}, {'id': 'EG018', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.', 'otherNumAtRisk': 12, 'otherNumAffected': 2, 'seriousNumAtRisk': 12, 'seriousNumAffected': 0}, {'id': 'EG019', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.', 'otherNumAtRisk': 12, 'otherNumAffected': 0, 'seriousNumAtRisk': 12, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Lymphadenopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Palpitations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 3}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Nodule', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Vessel puncture site haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 4}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 4}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 7}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 6}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 2}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Musculoskeletal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Presyncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Abnormal dreams', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Urine flow decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Skin irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Flushing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 9, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 12, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Supine Systolic Blood Pressure (SBP): Baseline', 'categories': [{'measurements': [{'value': '114.2', 'spread': '11.97', 'groupId': 'OG000'}, {'value': '110.6', 'spread': '6.70', 'groupId': 'OG001'}, {'value': '108.7', 'spread': '7.76', 'groupId': 'OG002'}, {'value': '102.8', 'spread': '6.62', 'groupId': 'OG003'}, {'value': '117.8', 'spread': '9.54', 'groupId': 'OG004'}, {'value': '112.4', 'spread': '12.26', 'groupId': 'OG005'}, {'value': '115.3', 'spread': '5.99', 'groupId': 'OG006'}]}]}, {'title': 'Supine SBP: Change at Day 1', 'categories': [{'measurements': [{'value': '-2.6', 'spread': '6.40', 'groupId': 'OG000'}, {'value': '-8.1', 'spread': '9.32', 'groupId': 'OG001'}, {'value': '1.0', 'spread': '8.17', 'groupId': 'OG002'}, {'value': '9.5', 'spread': '5.96', 'groupId': 'OG003'}, {'value': '-1.5', 'spread': '4.64', 'groupId': 'OG004'}, {'value': '2.1', 'spread': '11.28', 'groupId': 'OG005'}, {'value': '-5.3', 'spread': '7.91', 'groupId': 'OG006'}]}]}, {'title': 'Supine Diastolic blood pressure (DBP): Baseline', 'categories': [{'measurements': [{'value': '64.0', 'spread': '8.55', 'groupId': 'OG000'}, {'value': '67.0', 'spread': '8.77', 'groupId': 'OG001'}, {'value': '66.2', 'spread': '8.42', 'groupId': 'OG002'}, {'value': '58.7', 'spread': '8.19', 'groupId': 'OG003'}, {'value': '70.3', 'spread': '7.39', 'groupId': 'OG004'}, {'value': '66.9', 'spread': '8.98', 'groupId': 'OG005'}, {'value': '70.5', 'spread': '5.88', 'groupId': 'OG006'}]}]}, {'title': 'Supine DBP: Change at Day 1', 'categories': [{'measurements': [{'value': '-1.1', 'spread': '7.44', 'groupId': 'OG000'}, {'value': '-5.3', 'spread': '9.05', 'groupId': 'OG001'}, {'value': '2.2', 'spread': '9.56', 'groupId': 'OG002'}, {'value': '4.7', 'spread': '715', 'groupId': 'OG003'}, {'value': '2.5', 'spread': '8.83', 'groupId': 'OG004'}, {'value': '-0.1', 'spread': '8.36', 'groupId': 'OG005'}, {'value': '-2.3', 'spread': '6.14', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'unitOfMeasure': 'millimeter of mercury (mmHg)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS) included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Supine SBP: Baseline (n=9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '112.2', 'spread': '9.78', 'groupId': 'OG000'}, {'value': '106.5', 'spread': '3.54', 'groupId': 'OG001'}, {'value': '103.6', 'spread': '7.64', 'groupId': 'OG002'}, {'value': '110.3', 'spread': '5.19', 'groupId': 'OG003'}, {'value': '111.5', 'spread': '13.35', 'groupId': 'OG004'}, {'value': '108.6', 'spread': '18.45', 'groupId': 'OG005'}, {'value': '115.8', 'spread': '8.66', 'groupId': 'OG006'}]}]}, {'title': 'Supine SBP: Change at Day 10 (n=9,2,5,3,6,4,4)', 'categories': [{'measurements': [{'value': '4.0', 'spread': '9.12', 'groupId': 'OG000'}, {'value': '12.5', 'spread': '2.12', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '7.69', 'groupId': 'OG002'}, {'value': '8.7', 'spread': '10.69', 'groupId': 'OG003'}, {'value': '7.7', 'spread': '12.97', 'groupId': 'OG004'}, {'value': '-3.5', 'spread': '8.89', 'groupId': 'OG005'}, {'value': '-5.3', 'spread': '4.86', 'groupId': 'OG006'}]}]}, {'title': 'Supine DBP: Baseline (n=9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '60.3', 'spread': '4.15', 'groupId': 'OG000'}, {'value': '61.5', 'spread': '7.78', 'groupId': 'OG001'}, {'value': '56.2', 'spread': '4.02', 'groupId': 'OG002'}, {'value': '65.5', 'spread': '3.70', 'groupId': 'OG003'}, {'value': '68.8', 'spread': '9.06', 'groupId': 'OG004'}, {'value': '59.2', 'spread': '16.80', 'groupId': 'OG005'}, {'value': '66.2', 'spread': '8.06', 'groupId': 'OG006'}]}]}, {'title': 'Supine DBP: Change at Day 10 (n=9,2,5,3,6,4,4)', 'categories': [{'measurements': [{'value': '4.2', 'spread': '7.26', 'groupId': 'OG000'}, {'value': '6.0', 'spread': '4.24', 'groupId': 'OG001'}, {'value': '2.2', 'spread': '6.76', 'groupId': 'OG002'}, {'value': '5.7', 'spread': '1.53', 'groupId': 'OG003'}, {'value': '3.2', 'spread': '9.62', 'groupId': 'OG004'}, {'value': '-4.3', 'spread': '9.14', 'groupId': 'OG005'}, {'value': '2.0', 'spread': '5.48', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Supine SBP: Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '115.0', 'spread': '13.21', 'groupId': 'OG000'}, {'value': '120.1', 'spread': '10.91', 'groupId': 'OG001'}, {'value': '112.9', 'spread': '8.11', 'groupId': 'OG002'}]}]}, {'title': 'Supine SBP: Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-5.3', 'spread': '11.87', 'groupId': 'OG000'}, {'value': '-8.9', 'spread': '9.94', 'groupId': 'OG001'}, {'value': '1.0', 'spread': '11.94', 'groupId': 'OG002'}]}]}, {'title': 'Supine DBP: Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '67.8', 'spread': '7.93', 'groupId': 'OG000'}, {'value': '69.9', 'spread': '7.94', 'groupId': 'OG001'}, {'value': '66.6', 'spread': '7.55', 'groupId': 'OG002'}]}]}, {'title': 'Supine DBP: Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '-7.0', 'spread': '6.00', 'groupId': 'OG001'}, {'value': '-0.8', 'spread': '16.96', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '57.5', 'spread': '6.36', 'groupId': 'OG000'}, {'value': '68.6', 'spread': '13.81', 'groupId': 'OG001'}, {'value': '67.2', 'spread': '9.66', 'groupId': 'OG002'}, {'value': '56.0', 'spread': '8.05', 'groupId': 'OG003'}, {'value': '67.3', 'spread': '9.24', 'groupId': 'OG004'}, {'value': '55.8', 'spread': '11.77', 'groupId': 'OG005'}, {'value': '57.8', 'spread': '6.54', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 1', 'categories': [{'measurements': [{'value': '1.0', 'spread': '3.42', 'groupId': 'OG000'}, {'value': '6.1', 'spread': '7.58', 'groupId': 'OG001'}, {'value': '2.5', 'spread': '6.28', 'groupId': 'OG002'}, {'value': '3.0', 'spread': '8.10', 'groupId': 'OG003'}, {'value': '0.7', 'spread': '5.54', 'groupId': 'OG004'}, {'value': '-1.1', 'spread': '3.94', 'groupId': 'OG005'}, {'value': '2.6', 'spread': '6.39', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'unitOfMeasure': 'beats per minute (bpm)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n =9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '59.3', 'spread': '12.58', 'groupId': 'OG000'}, {'value': '59.0', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '55.8', 'spread': '7.36', 'groupId': 'OG002'}, {'value': '60.8', 'spread': '4.99', 'groupId': 'OG003'}, {'value': '61.5', 'spread': '7.50', 'groupId': 'OG004'}, {'value': '66.0', 'spread': '9.43', 'groupId': 'OG005'}, {'value': '60.5', 'spread': '9.61', 'groupId': 'OG006'}]}]}, {'title': 'Change at Week 10 (n =9,2,5,3,6,4,4,)', 'categories': [{'measurements': [{'value': '-2.3', 'spread': '12.21', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '0.71', 'groupId': 'OG001'}, {'value': '-1.6', 'spread': '5.18', 'groupId': 'OG002'}, {'value': '-4.0', 'spread': '7.21', 'groupId': 'OG003'}, {'value': '-6.3', 'spread': '8.24', 'groupId': 'OG004'}, {'value': '-2.5', 'spread': '4.43', 'groupId': 'OG005'}, {'value': '-1.0', 'spread': '6.38', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'unitOfMeasure': 'bpm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '61.8', 'spread': '8.07', 'groupId': 'OG000'}, {'value': '61.4', 'spread': '9.52', 'groupId': 'OG001'}, {'value': '64.9', 'spread': '6.04', 'groupId': 'OG002'}]}]}, {'title': 'Change at Week 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-1.9', 'spread': '5.38', 'groupId': 'OG000'}, {'value': '-5.3', 'spread': '7.41', 'groupId': 'OG001'}, {'value': '-3.0', 'spread': '3.39', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'unitOfMeasure': 'bpm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '36.79', 'spread': '0.155', 'groupId': 'OG000'}, {'value': '36.83', 'spread': '0.359', 'groupId': 'OG001'}, {'value': '36.65', 'spread': '0.187', 'groupId': 'OG002'}, {'value': '36.82', 'spread': '0.194', 'groupId': 'OG003'}, {'value': '36.80', 'spread': '0.141', 'groupId': 'OG004'}, {'value': '36.69', 'spread': '0.164', 'groupId': 'OG005'}, {'value': '36.63', 'spread': '0.149', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 1', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.151', 'groupId': 'OG000'}, {'value': '-0.11', 'spread': '0.418', 'groupId': 'OG001'}, {'value': '0.35', 'spread': '0.281', 'groupId': 'OG002'}, {'value': '0.05', 'spread': '0.235', 'groupId': 'OG003'}, {'value': '0.07', 'spread': '0.103', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.238', 'groupId': 'OG005'}, {'value': '0.05', 'spread': '0.177', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'unitOfMeasure': 'degree celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '36.71', 'spread': '0.136', 'groupId': 'OG000'}, {'value': '36.70', 'spread': '0.141', 'groupId': 'OG001'}, {'value': '36.76', 'spread': '0.182', 'groupId': 'OG002'}, {'value': '36.68', 'spread': '0.126', 'groupId': 'OG003'}, {'value': '36.83', 'spread': '0.163', 'groupId': 'OG004'}, {'value': '36.76', 'spread': '0.167', 'groupId': 'OG005'}, {'value': '36.75', 'spread': '0.235', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.228', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.071', 'groupId': 'OG001'}, {'value': '-0.22', 'spread': '0.164', 'groupId': 'OG002'}, {'value': '-0.10', 'spread': '0.100', 'groupId': 'OG003'}, {'value': '-0.22', 'spread': '0.214', 'groupId': 'OG004'}, {'value': '-0.17', 'spread': '0.206', 'groupId': 'OG005'}, {'value': '0.05', 'spread': '0.208', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'unitOfMeasure': 'degree celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n = 9, 14, 7)', 'categories': [{'measurements': [{'value': '36.74', 'spread': '0.151', 'groupId': 'OG000'}, {'value': '36.67', 'spread': '0.213', 'groupId': 'OG001'}, {'value': '36.80', 'spread': '0.277', 'groupId': 'OG002'}]}]}, {'title': 'Change at Week 28 (n= 8, 7, 5)', 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.223', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.369', 'groupId': 'OG001'}, {'value': '-0.20', 'spread': '0.300', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'unitOfMeasure': 'degrees celsius', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Number of Participants With Change From Baseline in Physical Examinations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '9', 'groupId': 'OG014'}, {'value': '14', 'groupId': 'OG015'}, {'value': '7', 'groupId': 'OG016'}, {'value': '12', 'groupId': 'OG017'}, {'value': '12', 'groupId': 'OG018'}, {'value': '12', 'groupId': 'OG019'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG007', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG008', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG013', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG014', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG015', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG016', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG017', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG018', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG019', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '3', 'groupId': 'OG015'}, {'value': '0', 'groupId': 'OG016'}, {'value': '0', 'groupId': 'OG017'}, {'value': '0', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': 'Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'PR Interval: Baseline', 'categories': [{'measurements': [{'value': '175.7', 'spread': '14.52', 'groupId': 'OG000'}, {'value': '149.7', 'spread': '18.62', 'groupId': 'OG001'}, {'value': '163.1', 'spread': '13.58', 'groupId': 'OG002'}, {'value': '168.2', 'spread': '14.63', 'groupId': 'OG003'}, {'value': '163.6', 'spread': '19.37', 'groupId': 'OG004'}, {'value': '175.8', 'spread': '18.86', 'groupId': 'OG005'}, {'value': '165.9', 'spread': '7.65', 'groupId': 'OG006'}]}]}, {'title': 'PR Interval: Change at Day 1', 'categories': [{'measurements': [{'value': '-0.9', 'spread': '6.78', 'groupId': 'OG000'}, {'value': '6.7', 'spread': '8.12', 'groupId': 'OG001'}, {'value': '-2.4', 'spread': '6.65', 'groupId': 'OG002'}, {'value': '2.2', 'spread': '5.45', 'groupId': 'OG003'}, {'value': '-2.1', 'spread': '5.95', 'groupId': 'OG004'}, {'value': '3.3', 'spread': '5.62', 'groupId': 'OG005'}, {'value': '0.5', 'spread': '7.54', 'groupId': 'OG006'}]}]}, {'title': 'QRS Complex: Baseline', 'categories': [{'measurements': [{'value': '97.7', 'spread': '15.40', 'groupId': 'OG000'}, {'value': '92.9', 'spread': '9.30', 'groupId': 'OG001'}, {'value': '97.4', 'spread': '10.43', 'groupId': 'OG002'}, {'value': '102.9', 'spread': '8.74', 'groupId': 'OG003'}, {'value': '99.8', 'spread': '14.61', 'groupId': 'OG004'}, {'value': '101.7', 'spread': '6.87', 'groupId': 'OG005'}, {'value': '92.0', 'spread': '5.81', 'groupId': 'OG006'}]}]}, {'title': 'QRS Complex: Change at Day 1', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '12.73', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '5.98', 'groupId': 'OG001'}, {'value': '-2.2', 'spread': '4.06', 'groupId': 'OG002'}, {'value': '-1.7', 'spread': '3.55', 'groupId': 'OG003'}, {'value': '-2.9', 'spread': '3.45', 'groupId': 'OG004'}, {'value': '-2.0', 'spread': '5.19', 'groupId': 'OG005'}, {'value': '1.7', 'spread': '2.33', 'groupId': 'OG006'}]}]}, {'title': 'QT Interval: Baseline', 'categories': [{'measurements': [{'value': '408.4', 'spread': '21.42', 'groupId': 'OG000'}, {'value': '374.0', 'spread': '21.81', 'groupId': 'OG001'}, {'value': '384.3', 'spread': '26.20', 'groupId': 'OG002'}, {'value': '404.2', 'spread': '19.89', 'groupId': 'OG003'}, {'value': '387.5', 'spread': '12.0', 'groupId': 'OG004'}, {'value': '421.3', 'spread': '29.94', 'groupId': 'OG005'}, {'value': '407.1', 'spread': '20.71', 'groupId': 'OG006'}]}]}, {'title': 'QT Interval: Change at Day 1', 'categories': [{'measurements': [{'value': '-5.9', 'spread': '10.41', 'groupId': 'OG000'}, {'value': '-3.8', 'spread': '10.21', 'groupId': 'OG001'}, {'value': '-3.1', 'spread': '9.43', 'groupId': 'OG002'}, {'value': '-8.2', 'spread': '9.25', 'groupId': 'OG003'}, {'value': '-0.8', 'spread': '4.56', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '11.61', 'groupId': 'OG005'}, {'value': '-3.3', 'spread': '14.78', 'groupId': 'OG006'}]}]}, {'title': 'QTC Interval: Baseline', 'categories': [{'measurements': [{'value': '397.7', 'spread': '16.51', 'groupId': 'OG000'}, {'value': '390.9', 'spread': '20.95', 'groupId': 'OG001'}, {'value': '400.6', 'spread': '11.90', 'groupId': 'OG002'}, {'value': '392.2', 'spread': '13.42', 'groupId': 'OG003'}, {'value': '402.7', 'spread': '20.69', 'groupId': 'OG004'}, {'value': '400.0', 'spread': '7.60', 'groupId': 'OG005'}, {'value': '402.7', 'spread': '14.10', 'groupId': 'OG006'}]}]}, {'title': 'QTC Interval: Change at Day 1', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '9.24', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '5.45', 'groupId': 'OG001'}, {'value': '-1.9', 'spread': '7.61', 'groupId': 'OG002'}, {'value': '2.4', 'spread': '9.42', 'groupId': 'OG003'}, {'value': '-4.6', 'spread': '4.41', 'groupId': 'OG004'}, {'value': '4.2', 'spread': '7.75', 'groupId': 'OG005'}, {'value': '3.2', 'spread': '5.76', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'unitOfMeasure': 'millisecond (msec)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'PR Interval: Baseline (n =9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '176.9', 'spread': '16.31', 'groupId': 'OG000'}, {'value': '180.0', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '167.6', 'spread': '10.69', 'groupId': 'OG002'}, {'value': '169.0', 'spread': '22.38', 'groupId': 'OG003'}, {'value': '168.5', 'spread': '18.79', 'groupId': 'OG004'}, {'value': '171.6', 'spread': '14.77', 'groupId': 'OG005'}, {'value': '168.0', 'spread': '6.66', 'groupId': 'OG006'}]}]}, {'title': 'PR Interval: Change at Day 10 (n =9,2,5,3,6,4,4)', 'categories': [{'measurements': [{'value': '5.2', 'spread': '3.59', 'groupId': 'OG000'}, {'value': '4.7', 'spread': '6.60', 'groupId': 'OG001'}, {'value': '7.7', 'spread': '5.36', 'groupId': 'OG002'}, {'value': '14.3', 'spread': '8.41', 'groupId': 'OG003'}, {'value': '7.3', 'spread': '10.07', 'groupId': 'OG004'}, {'value': '11.2', 'spread': '5.14', 'groupId': 'OG005'}, {'value': '1.4', 'spread': '2.33', 'groupId': 'OG006'}]}]}, {'title': 'QRS Complex: Baseline (n =9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '96.6', 'spread': '5.83', 'groupId': 'OG000'}, {'value': '96.0', 'spread': '7.07', 'groupId': 'OG001'}, {'value': '103.0', 'spread': '9.14', 'groupId': 'OG002'}, {'value': '101.0', 'spread': '20.05', 'groupId': 'OG003'}, {'value': '102.7', 'spread': '8.52', 'groupId': 'OG004'}, {'value': '103.0', 'spread': '8.34', 'groupId': 'OG005'}, {'value': '95.2', 'spread': '8.70', 'groupId': 'OG006'}]}]}, {'title': 'QRS Complex: Change at Day 10 (n =9,2,5,3,6,4,4)', 'categories': [{'measurements': [{'value': '0.9', 'spread': '1.60', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '6.36', 'groupId': 'OG001'}, {'value': '-3.2', 'spread': '9.49', 'groupId': 'OG002'}, {'value': '-2.3', 'spread': '6.17', 'groupId': 'OG003'}, {'value': '1.3', 'spread': '5.32', 'groupId': 'OG004'}, {'value': '2.9', 'spread': '5.26', 'groupId': 'OG005'}, {'value': '-1.7', 'spread': '1.83', 'groupId': 'OG006'}]}]}, {'title': 'QT Interval: Baseline (n =9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '411.9', 'spread': '27.98', 'groupId': 'OG000'}, {'value': '425.5', 'spread': '10.61', 'groupId': 'OG001'}, {'value': '407.4', 'spread': '18.17', 'groupId': 'OG002'}, {'value': '398.0', 'spread': '9.56', 'groupId': 'OG003'}, {'value': '399.7', 'spread': '16.12', 'groupId': 'OG004'}, {'value': '397.0', 'spread': '23.29', 'groupId': 'OG005'}, {'value': '401.8', 'spread': '27.66', 'groupId': 'OG006'}]}]}, {'title': 'QT Interval: Change at Day 10 (n =9,2,5,3,6,4,4)', 'categories': [{'measurements': [{'value': '-3.9', 'spread': '14.72', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '11.79', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '23.42', 'groupId': 'OG002'}, {'value': '2.6', 'spread': '9.26', 'groupId': 'OG003'}, {'value': '1.3', 'spread': '16.66', 'groupId': 'OG004'}, {'value': '2.3', 'spread': '5.51', 'groupId': 'OG005'}, {'value': '2.1', 'spread': '23.19', 'groupId': 'OG006'}]}]}, {'title': 'QTC Interval: Baseline (n =9,2,5,4,6,5,6)', 'categories': [{'measurements': [{'value': '398.7', 'spread': '11.35', 'groupId': 'OG000'}, {'value': '415.5', 'spread': '4.95', 'groupId': 'OG001'}, {'value': '396.4', 'spread': '15.53', 'groupId': 'OG002'}, {'value': '401.5', 'spread': '15.37', 'groupId': 'OG003'}, {'value': '396.0', 'spread': '6.54', 'groupId': 'OG004'}, {'value': '403.2', 'spread': '6.26', 'groupId': 'OG005'}, {'value': '403.5', 'spread': '11.96', 'groupId': 'OG006'}]}]}, {'title': 'QTC Interval: Change at Day 10 (n =9,2,5,3,6,4,4)', 'categories': [{'measurements': [{'value': '-0.3', 'spread': '9.82', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '10.14', 'groupId': 'OG001'}, {'value': '-2.9', 'spread': '3.00', 'groupId': 'OG002'}, {'value': '-5.0', 'spread': '10.49', 'groupId': 'OG003'}, {'value': '-1.3', 'spread': '10.34', 'groupId': 'OG004'}, {'value': '-0.3', 'spread': '4.46', 'groupId': 'OG005'}, {'value': '2.0', 'spread': '10.47', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'unitOfMeasure': 'msec', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'PR Interval: Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '169.4', 'spread': '15.26', 'groupId': 'OG000'}, {'value': '156.1', 'spread': '17.78', 'groupId': 'OG001'}, {'value': '154.7', 'spread': '11.51', 'groupId': 'OG002'}]}]}, {'title': 'PR Interval: Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-0.6', 'spread': '10.19', 'groupId': 'OG000'}, {'value': '11.1', 'spread': '5.95', 'groupId': 'OG001'}, {'value': '4.1', 'spread': '7.09', 'groupId': 'OG002'}]}]}, {'title': 'QRS Complex: Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '100.6', 'spread': '8.32', 'groupId': 'OG000'}, {'value': '97.4', 'spread': '10.27', 'groupId': 'OG001'}, {'value': '93.0', 'spread': '5.87', 'groupId': 'OG002'}]}]}, {'title': 'QRS Complex: Change at Day 28 (n= 8, 7, 5)', 'categories': [{'measurements': [{'value': '0.5', 'spread': '4.86', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '4.73', 'groupId': 'OG001'}, {'value': '3.8', 'spread': '5.26', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval: Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '404.4', 'spread': '17.48', 'groupId': 'OG000'}, {'value': '411.6', 'spread': '31.01', 'groupId': 'OG001'}, {'value': '379.0', 'spread': '18.94', 'groupId': 'OG002'}]}]}, {'title': 'QT Interval: Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-17.9', 'spread': '16.00', 'groupId': 'OG000'}, {'value': '-22.6', 'spread': '23.04', 'groupId': 'OG001'}, {'value': '-5.3', 'spread': '9.43', 'groupId': 'OG002'}]}]}, {'title': 'QTC Interval: Baseline (n=9, 14, 7)', 'categories': [{'measurements': [{'value': '409.7', 'spread': '14.46', 'groupId': 'OG000'}, {'value': '409.0', 'spread': '14.92', 'groupId': 'OG001'}, {'value': '392.0', 'spread': '19.04', 'groupId': 'OG002'}]}]}, {'title': 'QTC Interval: Change at Day 28 (n= 8, 7, 5)', 'categories': [{'measurements': [{'value': '-8.7', 'spread': '10.83', 'groupId': 'OG000'}, {'value': '-9.6', 'spread': '7.89', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '13.18', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'unitOfMeasure': 'msec', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '56.1', 'spread': '6.83', 'groupId': 'OG000'}, {'value': '70.3', 'spread': '16.46', 'groupId': 'OG001'}, {'value': '69.2', 'spread': '12.06', 'groupId': 'OG002'}, {'value': '55.3', 'spread': '5.65', 'groupId': 'OG003'}, {'value': '67.7', 'spread': '8.82', 'groupId': 'OG004'}, {'value': '53.0', 'spread': '8.92', 'groupId': 'OG005'}, {'value': '58.0', 'spread': '5.17', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 1', 'categories': [{'measurements': [{'value': '2.2', 'spread': '3.74', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '2.81', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '3.27', 'groupId': 'OG002'}, {'value': '4.6', 'spread': '4.64', 'groupId': 'OG003'}, {'value': '-2.3', 'spread': '1.72', 'groupId': 'OG004'}, {'value': '2.0', 'spread': '3.19', 'groupId': 'OG005'}, {'value': '3.4', 'spread': '5.79', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'unitOfMeasure': 'bpm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '55.1', 'spread': '7.15', 'groupId': 'OG000'}, {'value': '55.5', 'spread': '2.12', 'groupId': 'OG001'}, {'value': '55.4', 'spread': '4.45', 'groupId': 'OG002'}, {'value': '61.0', 'spread': '2.94', 'groupId': 'OG003'}, {'value': '58.5', 'spread': '6.38', 'groupId': 'OG004'}, {'value': '63.0', 'spread': '7.38', 'groupId': 'OG005'}, {'value': '61.2', 'spread': '7.96', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 10 (n = 9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '10.33', 'groupId': 'OG000'}, {'value': '7.7', 'spread': '6.13', 'groupId': 'OG001'}, {'value': '-1.1', 'spread': '7.22', 'groupId': 'OG002'}, {'value': '-3.0', 'spread': '4.04', 'groupId': 'OG003'}, {'value': '-2.3', 'spread': '5.12', 'groupId': 'OG004'}, {'value': '-1.8', 'spread': '5.79', 'groupId': 'OG005'}, {'value': '-1.3', 'spread': '4.04', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'unitOfMeasure': 'bpm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '63.1', 'spread': '9.15', 'groupId': 'OG000'}, {'value': '60.2', 'spread': '11.25', 'groupId': 'OG001'}, {'value': '66.0', 'spread': '4.93', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '5.2', 'spread': '5.28', 'groupId': 'OG000'}, {'value': '4.0', 'spread': '8.73', 'groupId': 'OG001'}, {'value': '1.4', 'spread': '5.60', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'unitOfMeasure': 'bpm', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '9', 'groupId': 'OG014'}, {'value': '14', 'groupId': 'OG015'}, {'value': '7', 'groupId': 'OG016'}, {'value': '12', 'groupId': 'OG017'}, {'value': '12', 'groupId': 'OG018'}, {'value': '12', 'groupId': 'OG019'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG007', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG008', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG013', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG014', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG015', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG016', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG017', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG018', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG019', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'title': 'AEs', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}, {'value': '3', 'groupId': 'OG009'}, {'value': '2', 'groupId': 'OG010'}, {'value': '3', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '5', 'groupId': 'OG013'}, {'value': '5', 'groupId': 'OG014'}, {'value': '11', 'groupId': 'OG015'}, {'value': '6', 'groupId': 'OG016'}, {'value': '1', 'groupId': 'OG017'}, {'value': '2', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}, {'value': '0', 'groupId': 'OG016'}, {'value': '0', 'groupId': 'OG017'}, {'value': '0', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}, {'title': 'Withdrawal due to AEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '6', 'groupId': 'OG015'}, {'value': '1', 'groupId': 'OG016'}, {'value': '0', 'groupId': 'OG017'}, {'value': '0', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Number of Adverse Events (AEs) According to Severity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '9', 'groupId': 'OG014'}, {'value': '14', 'groupId': 'OG015'}, {'value': '7', 'groupId': 'OG016'}, {'value': '12', 'groupId': 'OG017'}, {'value': '12', 'groupId': 'OG018'}, {'value': '12', 'groupId': 'OG019'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG007', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG008', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG013', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG014', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG015', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG016', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG017', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG018', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG019', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'title': 'Mild', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}, {'value': '3', 'groupId': 'OG009'}, {'value': '2', 'groupId': 'OG010'}, {'value': '2', 'groupId': 'OG011'}, {'value': '6', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '7', 'groupId': 'OG014'}, {'value': '16', 'groupId': 'OG015'}, {'value': '16', 'groupId': 'OG016'}, {'value': '1', 'groupId': 'OG017'}, {'value': '2', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}, {'title': 'Moderate', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '1', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '1', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}, {'value': '0', 'groupId': 'OG016'}, {'value': '0', 'groupId': 'OG017'}, {'value': '0', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}, {'title': 'Severe', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}, {'value': '0', 'groupId': 'OG011'}, {'value': '0', 'groupId': 'OG012'}, {'value': '0', 'groupId': 'OG013'}, {'value': '0', 'groupId': 'OG014'}, {'value': '0', 'groupId': 'OG015'}, {'value': '0', 'groupId': 'OG016'}, {'value': '0', 'groupId': 'OG017'}, {'value': '0', 'groupId': 'OG018'}, {'value': '0', 'groupId': 'OG019'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': "An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.", 'unitOfMeasure': 'adverse events', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Laboratory Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '2', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '9', 'groupId': 'OG014'}, {'value': '14', 'groupId': 'OG015'}, {'value': '7', 'groupId': 'OG016'}, {'value': '12', 'groupId': 'OG017'}, {'value': '12', 'groupId': 'OG018'}, {'value': '12', 'groupId': 'OG019'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG007', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG008', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG013', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG014', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG015', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG016', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG017', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG018', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG019', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '6', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '6', 'groupId': 'OG013'}, {'value': '7', 'groupId': 'OG014'}, {'value': '13', 'groupId': 'OG015'}, {'value': '7', 'groupId': 'OG016'}, {'value': '5', 'groupId': 'OG017'}, {'value': '1', 'groupId': 'OG018'}, {'value': '3', 'groupId': 'OG019'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': 'Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(\\<) 0.8\\*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: \\<0.9\\*LLN,\\>1.1\\*upper limit of normal (ULN); platelets: \\<0.5\\*LLN,\\>1.75\\*ULN, white blood cell count: \\<0.6\\*LLN, \\>1.5\\*ULN; lymphocytes, total neutrophils: \\<0.8\\*LLN, \\>1.2\\*ULN; eosinophils, basophils, monocytes: \\>1.2\\*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: \\>1.1\\*ULN; liver function: bilirubin: \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \\>3.0\\*ULN; protein, albumin: \\<0.8\\*LLN\\>\\</0\\>1.2\\*ULN; renal function:blood urea nitrogen,creatinine: \\>1.3\\*ULN; uric acid: \\>1.2\\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \\<0.9\\*LLN,\\>1.1\\*ULN; urinalysis: pH\\<4.5, \\>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \\<0.6\\*LLN,\\>1.5\\*ULN)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FAS included all participants who were randomized to treatment and received at least 1 dose of study medication.'}, {'type': 'PRIMARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '117.7', 'spread': '28.70', 'groupId': 'OG000'}, {'value': '93.0', 'spread': '36.60', 'groupId': 'OG001'}, {'value': '133.8', 'spread': '29.76', 'groupId': 'OG002'}, {'value': '95.8', 'spread': '53.07', 'groupId': 'OG003'}, {'value': '117.0', 'spread': '28.70', 'groupId': 'OG004'}, {'value': '129.6', 'spread': '25.43', 'groupId': 'OG005'}, {'value': '114.4', 'spread': '24.64', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 1', 'categories': [{'measurements': [{'value': '24.3', 'spread': '63.75', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '35.35', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '11.27', 'groupId': 'OG002'}, {'value': '15.8', 'spread': '36.79', 'groupId': 'OG003'}, {'value': '-6.4', 'spread': '6.35', 'groupId': 'OG004'}, {'value': '-17.6', 'spread': '28.67', 'groupId': 'OG005'}, {'value': '73.4', 'spread': '227.50', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'description': 'Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.', 'unitOfMeasure': 'milliliter per minute (mL/min)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '9', 'groupId': 'OG007'}, {'value': '14', 'groupId': 'OG008'}, {'value': '7', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 2, 5, 4, 6, 5, 6, 2, 2, 7)', 'categories': [{'measurements': [{'value': '114.4', 'spread': '27.75', 'groupId': 'OG000'}, {'value': '111.0', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '112.6', 'spread': '42.08', 'groupId': 'OG002'}, {'value': '115.0', 'spread': '34.13', 'groupId': 'OG003'}, {'value': '142.5', 'spread': '56.68', 'groupId': 'OG004'}, {'value': '138.4', 'spread': '51.27', 'groupId': 'OG005'}, {'value': '83.0', 'spread': '39.73', 'groupId': 'OG006'}, {'value': '140.5', 'spread': '55.86', 'groupId': 'OG007'}, {'value': '158.0', 'spread': '36.77', 'groupId': 'OG008'}, {'value': '172.4', 'spread': '51.74', 'groupId': 'OG009'}]}]}, {'title': 'Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4, 2, 2, 7)', 'categories': [{'measurements': [{'value': '0.7', 'spread': '33.29', 'groupId': 'OG000'}, {'value': '-2.5', 'spread': '57.28', 'groupId': 'OG001'}, {'value': '26.8', 'spread': '46.90', 'groupId': 'OG002'}, {'value': '-19.0', 'spread': '25.51', 'groupId': 'OG003'}, {'value': '-47.0', 'spread': '55.68', 'groupId': 'OG004'}, {'value': '-39.5', 'spread': '29.86', 'groupId': 'OG005'}, {'value': '3.5', 'spread': '40.42', 'groupId': 'OG006'}, {'value': '-38.5', 'spread': '60.10', 'groupId': 'OG007'}, {'value': '-50.0', 'spread': '4.24', 'groupId': 'OG008'}, {'value': '-67.3', 'spread': '61.45', 'groupId': 'OG009'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'description': 'Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.', 'unitOfMeasure': 'mL/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively."}, {'type': 'PRIMARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '-10.0', 'spread': '0.0', 'groupId': 'OG000'}, {'value': '-35.0', 'spread': '33.94', 'groupId': 'OG001'}, {'value': '-67.6', 'spread': '50.33', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'description': 'Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.', 'unitOfMeasure': 'mL/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "FAS included all participants who were randomized to treatment and received at least 1 dose of study medication. Here, 'N' signifies those participants who were evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG001', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': '6463', 'spread': '46', 'groupId': 'OG000'}, {'value': '6720', 'spread': '43', 'groupId': 'OG001'}, {'value': '5321', 'spread': '53', 'groupId': 'OG002'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).', 'unitOfMeasure': 'nanogram*hour per milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.'}, {'type': 'PRIMARY', 'title': 'Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG001', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': '6447', 'spread': '46', 'groupId': 'OG000'}, {'value': '6694', 'spread': '43', 'groupId': 'OG001'}, {'value': '5305', 'spread': '53', 'groupId': 'OG002'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1', 'description': 'Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.'}, {'type': 'PRIMARY', 'title': 'Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG001', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': '1022', 'spread': '35', 'groupId': 'OG000'}, {'value': '1084', 'spread': '40', 'groupId': 'OG001'}, {'value': '656.6', 'spread': '26', 'groupId': 'OG002'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1', 'unitOfMeasure': 'nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest in at least 1 treatment period.'}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.138', 'spread': '52', 'groupId': 'OG000'}, {'value': '18.21', 'spread': '92', 'groupId': 'OG001'}, {'value': '79.30', 'spread': '35', 'groupId': 'OG002'}, {'value': '271.3', 'spread': '21', 'groupId': 'OG003'}, {'value': '748.4', 'spread': '35', 'groupId': 'OG004'}, {'value': '2460', 'spread': '37', 'groupId': 'OG005'}, {'value': '63.42', 'spread': '11', 'groupId': 'OG006'}, {'value': '286.6', 'spread': '17', 'groupId': 'OG007'}, {'value': '734.1', 'spread': '29', 'groupId': 'OG008'}, {'value': '522.0', 'spread': '31', 'groupId': 'OG009'}, {'value': '2091', 'spread': '28', 'groupId': 'OG010'}, {'value': '204.7', 'spread': '43', 'groupId': 'OG011'}, {'value': '924.2', 'spread': '13', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.00', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '1.00', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.500', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '1.00', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '1.00', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '1.00', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '1.00', 'groupId': 'OG006', 'lowerLimit': '1.00', 'upperLimit': '1.03'}, {'value': '1.00', 'groupId': 'OG007', 'lowerLimit': '1.00', 'upperLimit': '1.00'}, {'value': '1.50', 'groupId': 'OG008', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '1.00', 'groupId': 'OG009', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '0.984', 'groupId': 'OG010', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '1.00', 'groupId': 'OG011', 'lowerLimit': '0.983', 'upperLimit': '1.00'}, {'value': '2.00', 'groupId': 'OG012', 'lowerLimit': '1.00', 'upperLimit': '2.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28', 'unitOfMeasure': 'hour', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm"}, {'type': 'SECONDARY', 'title': 'Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG001', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.500', 'spread': '0.500', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '1.00', 'spread': '1.2965', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '4.00', 'spread': '1.4383', 'groupId': 'OG002', 'lowerLimit': '1.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1', 'unitOfMeasure': 'hour', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest.'}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '145.8', 'spread': '61', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '353.8', 'spread': '31', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '1439', 'spread': '65', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '4797', 'spread': '62', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '18410', 'spread': '46', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm"}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '7', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '422.8', 'spread': '41', 'groupId': 'OG000'}, {'value': '1880', 'spread': '52', 'groupId': 'OG001'}, {'value': '6089', 'spread': '38', 'groupId': 'OG002'}, {'value': '3560', 'spread': '35', 'groupId': 'OG003'}, {'value': '16180', 'spread': '15', 'groupId': 'OG004'}, {'value': '990.0', 'spread': '103', 'groupId': 'OG005'}, {'value': '7672', 'spread': '43', 'groupId': 'OG006'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28', 'description': 'Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: MAD Cohort, MAD Psoriasis Cohort arm"}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '17.71', 'spread': '114', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '79.18', 'spread': '239', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '340.4', 'spread': '30', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '1431', 'spread': '65', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '5041', 'spread': '59', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '18400', 'spread': '46', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm"}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.138', 'spread': '52', 'groupId': 'OG000'}, {'value': '6.061', 'spread': '92', 'groupId': 'OG001'}, {'value': '7.930', 'spread': '35', 'groupId': 'OG002'}, {'value': '9.033', 'spread': '21', 'groupId': 'OG003'}, {'value': '7.484', 'spread': '35', 'groupId': 'OG004'}, {'value': '12.31', 'spread': '37', 'groupId': 'OG005'}, {'value': '6.342', 'spread': '11', 'groupId': 'OG006'}, {'value': '9.563', 'spread': '17', 'groupId': 'OG007'}, {'value': '7.341', 'spread': '29', 'groupId': 'OG008'}, {'value': '10.43', 'spread': '30', 'groupId': 'OG009'}, {'value': '11.97', 'spread': '28', 'groupId': 'OG010'}, {'value': '6.827', 'spread': '43', 'groupId': 'OG011'}, {'value': '9.242', 'spread': '13', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28', 'description': 'Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.', 'unitOfMeasure': '[nanogram/milliliter]/milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '48.65', 'spread': '61', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '35.38', 'spread': '31', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '47.97', 'spread': '65', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '47.97', 'spread': '62', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '92.13', 'spread': '46', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.', 'unitOfMeasure': '[nanogram*hour/milliliter]/milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '17.71', 'spread': '114', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '26.38', 'spread': '239', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '34.04', 'spread': '30', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '47.64', 'spread': '65', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '50.41', 'spread': '59', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '92.09', 'spread': '46', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.', 'unitOfMeasure': '[ng*hr/mL]/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort arm."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '42.28', 'spread': '41', 'groupId': 'OG000'}, {'value': '62.68', 'spread': '51', 'groupId': 'OG001'}, {'value': '60.89', 'spread': '38', 'groupId': 'OG002'}, {'value': '71.15', 'spread': '36', 'groupId': 'OG003'}, {'value': '92.30', 'spread': '16', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10', 'description': 'Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.', 'unitOfMeasure': '[ng*hr/mL]/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}, {'value': '12', 'groupId': 'OG013'}, {'value': '12', 'groupId': 'OG014'}, {'value': '12', 'groupId': 'OG015'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG013', 'title': 'PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG014', 'title': 'PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in food effects cohort of the study.'}, {'id': 'OG015', 'title': 'PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)', 'description': 'All participants who received PF-06700841 100 mg tablet under fed condition in either 1 of the 3 treatment period in food effects cohort of the study.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '4.554', 'spread': '1.8066', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '3.848', 'spread': '1.1587', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '4.363', 'spread': '2.4126', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '7.519', 'spread': '2.8236', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '6.813', 'spread': '1.9875', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '5.928', 'spread': '3.3336', 'groupId': 'OG006', 'lowerLimit': '1.00', 'upperLimit': '1.03'}, {'value': '4.860', 'spread': '1.9304', 'groupId': 'OG007', 'lowerLimit': '1.00', 'upperLimit': '1.00'}, {'value': '10.67', 'spread': '1.8440', 'groupId': 'OG008', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '9.133', 'spread': '2.2579', 'groupId': 'OG009', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '7.458', 'spread': '2.1595', 'groupId': 'OG010', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '16.01', 'spread': '31.584', 'groupId': 'OG011', 'lowerLimit': '0.983', 'upperLimit': '2.00'}, {'value': '6.032', 'spread': '1.7121', 'groupId': 'OG012', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '6.155', 'spread': '1.4408', 'groupId': 'OG013', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '6.168', 'spread': '1.2965', 'groupId': 'OG014', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '5.848', 'spread': '1.4383', 'groupId': 'OG015', 'lowerLimit': '1.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'SAD: pre--dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre--dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28', 'description': 'Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.', 'unitOfMeasure': 'hour', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG000'}, {'value': '6.414', 'spread': '46', 'groupId': 'OG001'}, {'value': '5.169', 'spread': '34', 'groupId': 'OG002'}, {'value': '5.206', 'spread': '44', 'groupId': 'OG003'}, {'value': '7.277', 'spread': '37', 'groupId': 'OG004'}, {'value': '8.758', 'spread': '29', 'groupId': 'OG005'}, {'value': '7.191', 'spread': '45', 'groupId': 'OG006'}, {'value': '6.830', 'spread': '38', 'groupId': 'OG007'}, {'value': '10.35', 'spread': '25', 'groupId': 'OG008'}, {'value': '9.592', 'spread': '22', 'groupId': 'OG009'}, {'value': '9.025', 'spread': '26', 'groupId': 'OG010'}, {'value': '6.072', 'spread': '92', 'groupId': 'OG011'}, {'value': '8.534', 'spread': '36', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'SAD: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28', 'description': 'MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.', 'unitOfMeasure': 'hour', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '126.4', 'spread': '26', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '151.0', 'spread': '18', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '115.7', 'spread': '16', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '210.5', 'spread': '45', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '102.4', 'spread': '27', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '177.6', 'spread': '30', 'groupId': 'OG006', 'lowerLimit': '1.00', 'upperLimit': '1.03'}, {'value': '106.2', 'spread': '12', 'groupId': 'OG007', 'lowerLimit': '1.00', 'upperLimit': '1.00'}, {'value': '249.4', 'spread': '45', 'groupId': 'OG008', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '180.9', 'spread': '30', 'groupId': 'OG009', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '112.4', 'spread': '18', 'groupId': 'OG010', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '245.4', 'spread': '206', 'groupId': 'OG011', 'lowerLimit': '0.983', 'upperLimit': '2.00'}, {'value': '109.6', 'spread': '18', 'groupId': 'OG012', 'lowerLimit': '1.00', 'upperLimit': '2.00'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'unitOfMeasure': 'liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '3', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '4', 'groupId': 'OG010'}, {'value': '7', 'groupId': 'OG011'}, {'value': '5', 'groupId': 'OG012'}]}], 'groups': [{'id': 'OG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG007', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG008', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG009', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG010', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG011', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG012', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG000'}, {'value': '20.57', 'spread': '61', 'groupId': 'OG001'}, {'value': '28.26', 'spread': '31', 'groupId': 'OG002'}, {'value': '20.82', 'spread': '65', 'groupId': 'OG003'}, {'value': '20.85', 'spread': '61', 'groupId': 'OG004'}, {'value': '10.86', 'spread': '46', 'groupId': 'OG005'}, {'value': '23.65', 'spread': '41', 'groupId': 'OG006'}, {'value': '15.95', 'spread': '51', 'groupId': 'OG007'}, {'value': '16.43', 'spread': '38', 'groupId': 'OG008'}, {'value': '14.03', 'spread': '35', 'groupId': 'OG009'}, {'value': '10.83', 'spread': '16', 'groupId': 'OG010'}, {'value': '30.30', 'spread': '103', 'groupId': 'OG011'}, {'value': '13.04', 'spread': '43', 'groupId': 'OG012'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28', 'description': 'Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.', 'unitOfMeasure': 'Liter per hour (L/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: SAD Cohort, MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.815', 'spread': '40', 'groupId': 'OG000'}, {'value': '3.543', 'spread': '38', 'groupId': 'OG001'}, {'value': '2.643', 'spread': '31', 'groupId': 'OG002'}, {'value': '1.297', 'spread': '22', 'groupId': 'OG003'}, {'value': '2.911', 'spread': '43', 'groupId': 'OG004'}, {'value': '3.414', 'spread': '44', 'groupId': 'OG005'}, {'value': '2.654', 'spread': '42', 'groupId': 'OG006'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28', 'description': 'PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC\\[tau\\]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo: MAD Cohort, MAD Psoriasis Cohort arm."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.109', 'spread': '45', 'groupId': 'OG000'}, {'value': '2.798', 'spread': '57', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG002'}, {'value': '7.758', 'spread': '57', 'groupId': 'OG003'}, {'value': '15.60', 'spread': '44', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0-24 hour on Day 10', 'description': 'Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.', 'unitOfMeasure': 'milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.09', 'spread': '45', 'groupId': 'OG000'}, {'value': '9.332', 'spread': '57', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG002'}, {'value': '15.54', 'spread': '57', 'groupId': 'OG003'}, {'value': '8.910', 'spread': '44', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0-24 hours on Day 10', 'description': 'Aetau% was calculated as: 100\\*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.', 'unitOfMeasure': 'percentage of dose recovered', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Renal Clearance', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.619', 'spread': '18', 'groupId': 'OG000'}, {'value': '1.486', 'spread': '15', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Data was not collected due to less than 3 participants were evaluable and considered insufficient to calculate a reliable estimation, by investigator.', 'groupId': 'OG002'}, {'value': '2.179', 'spread': '31', 'groupId': 'OG003'}, {'value': '0.9629', 'spread': '58', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '0-24 hours on Day 10', 'description': 'Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.', 'unitOfMeasure': 'Liter per hour', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter analysis set included all randomized and treated participants who had at least 1 of the PK parameters of interest. Here, 'N' signifies those participants who were evaluable for this outcome measure. Data for this outcome was not planned to be analyzed for Placebo Once Daily and Twice Daily: MAD Cohort arms."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '119.17', 'spread': '40.090', 'groupId': 'OG000'}, {'value': '188.76', 'spread': '238.380', 'groupId': 'OG001'}, {'value': '219.62', 'spread': '275.440', 'groupId': 'OG002'}, {'value': '78.28', 'spread': '29.481', 'groupId': 'OG003'}, {'value': '141.38', 'spread': '100.403', 'groupId': 'OG004'}, {'value': '115.00', 'spread': '38.458', 'groupId': 'OG005'}, {'value': '114.33', 'spread': '26.164', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline', 'description': 'Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.', 'unitOfMeasure': 'picogram per milliliter (pg/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacodynamic (PD) analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest.'}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '114.04', 'spread': '70.658', 'groupId': 'OG000'}, {'value': '85.50', 'spread': '13.011', 'groupId': 'OG001'}, {'value': '101.12', 'spread': '56.853', 'groupId': 'OG002'}, {'value': '142.23', 'spread': '165.924', 'groupId': 'OG003'}, {'value': '106.43', 'spread': '28.244', 'groupId': 'OG004'}, {'value': '121.60', 'spread': '20.959', 'groupId': 'OG005'}, {'value': '135.42', 'spread': '57.855', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 2 (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '5.66', 'spread': '13.421', 'groupId': 'OG000'}, {'value': '2.00', 'spread': '13.294', 'groupId': 'OG001'}, {'value': '-20.14', 'spread': '41.966', 'groupId': 'OG002'}, {'value': '-23.60', 'spread': '82.888', 'groupId': 'OG003'}, {'value': '-47.52', 'spread': '19.664', 'groupId': 'OG004'}, {'value': '-60.64', 'spread': '16.913', 'groupId': 'OG005'}, {'value': '-67.73', 'spread': '35.998', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 5 (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '4.33', 'spread': '12.213', 'groupId': 'OG000'}, {'value': '-3.25', 'spread': '13.506', 'groupId': 'OG001'}, {'value': '-42.12', 'spread': '48.250', 'groupId': 'OG002'}, {'value': '-53.40', 'spread': '125.815', 'groupId': 'OG003'}, {'value': '-55.80', 'spread': '15.273', 'groupId': 'OG004'}, {'value': '-71.40', 'spread': '11.857', 'groupId': 'OG005'}, {'value': '-80.65', 'spread': '66.445', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-1.92', 'spread': '24.123', 'groupId': 'OG000'}, {'value': '4.75', 'spread': '9.687', 'groupId': 'OG001'}, {'value': '-40.10', 'spread': '43.129', 'groupId': 'OG002'}, {'value': '-96.67', 'spread': '134.176', 'groupId': 'OG003'}, {'value': '-57.22', 'spread': '9.321', 'groupId': 'OG004'}, {'value': '-70.50', 'spread': '14.007', 'groupId': 'OG005'}, {'value': '-106.40', 'spread': '60.163', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '11.01', 'spread': '19.008', 'groupId': 'OG000'}, {'value': '1.85', 'spread': '0.778', 'groupId': 'OG001'}, {'value': '-37.56', 'spread': '47.031', 'groupId': 'OG002'}, {'value': '-102.53', 'spread': '131.223', 'groupId': 'OG003'}, {'value': '-37.95', 'spread': '24.957', 'groupId': 'OG004'}, {'value': '-54.25', 'spread': '23.972', 'groupId': 'OG005'}, {'value': '-112.20', 'spread': '60.459', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-14.59', 'spread': '21.736', 'groupId': 'OG000'}, {'value': '2.85', 'spread': '11.102', 'groupId': 'OG001'}, {'value': '-11.76', 'spread': '51.955', 'groupId': 'OG002'}, {'value': '-62.07', 'spread': '94.378', 'groupId': 'OG003'}, {'value': '8.48', 'spread': '23.010', 'groupId': 'OG004'}, {'value': '18.30', 'spread': '34.748', 'groupId': 'OG005'}, {'value': '-47.15', 'spread': '89.356', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, 5, 10, 11, 28', 'description': 'Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '302.00', 'spread': '281.552', 'groupId': 'OG000'}, {'value': '127.58', 'spread': '45.829', 'groupId': 'OG001'}, {'value': '123.09', 'spread': '22.244', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 2 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '53.44', 'spread': '214.334', 'groupId': 'OG000'}, {'value': '-8.51', 'spread': '34.704', 'groupId': 'OG001'}, {'value': '-49.57', 'spread': '35.759', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 5 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '-21.63', 'spread': '142.195', 'groupId': 'OG000'}, {'value': '-33.93', 'spread': '33.465', 'groupId': 'OG001'}, {'value': '-49.01', 'spread': '35.998', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 7 (n =9, 12, 7)', 'categories': [{'measurements': [{'value': '-25.71', 'spread': '133.510', 'groupId': 'OG000'}, {'value': '-31.31', 'spread': '32.203', 'groupId': 'OG001'}, {'value': '-52.50', 'spread': '42.216', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 14 (n =9, 10, 6)', 'categories': [{'measurements': [{'value': '-69.91', 'spread': '106.951', 'groupId': 'OG000'}, {'value': '-52.06', 'spread': '24.663', 'groupId': 'OG001'}, {'value': '-68.55', 'spread': '28.524', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 21 (n =9, 9, 5)', 'categories': [{'measurements': [{'value': '-42.87', 'spread': '122.986', 'groupId': 'OG000'}, {'value': '-51.47', 'spread': '28.094', 'groupId': 'OG001'}, {'value': '-46.64', 'spread': '27.340', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-1.0', 'spread': '31.351', 'groupId': 'OG000'}, {'value': '-46.19', 'spread': '35.893', 'groupId': 'OG001'}, {'value': '-53.36', 'spread': '19.771', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 29 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-22.20', 'spread': '95.930', 'groupId': 'OG000'}, {'value': '-37.50', 'spread': '31.849', 'groupId': 'OG001'}, {'value': '-49.34', 'spread': '14.306', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 35 (n =8, 6, 5)', 'categories': [{'measurements': [{'value': '-69.54', 'spread': '124.165', 'groupId': 'OG000'}, {'value': '10.45', 'spread': '37.860', 'groupId': 'OG001'}, {'value': '110.68', 'spread': '108.041', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 56 (n =7, 6, 4)', 'categories': [{'measurements': [{'value': '-31.71', 'spread': '67.158', 'groupId': 'OG000'}, {'value': '16.18', 'spread': '19.348', 'groupId': 'OG001'}, {'value': '167.85', 'spread': '201.780', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56', 'description': 'Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.1220', 'spread': '0.11909', 'groupId': 'OG000'}, {'value': '0.1066', 'spread': '0.09662', 'groupId': 'OG001'}, {'value': '0.6420', 'spread': '1.41413', 'groupId': 'OG002'}, {'value': '0.0757', 'spread': '0.04523', 'groupId': 'OG003'}, {'value': '0.2290', 'spread': '0.11714', 'groupId': 'OG004'}, {'value': '0.1158', 'spread': '0.20871', 'groupId': 'OG005'}, {'value': '0.1710', 'spread': '0.10387', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline', 'description': 'Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.', 'unitOfMeasure': 'milligram per deciliter (mg/dL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest.'}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n= 9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '0.0974', 'spread': '0.06791', 'groupId': 'OG000'}, {'value': '0.0815', 'spread': '0.08556', 'groupId': 'OG001'}, {'value': '0.1002', 'spread': '0.11675', 'groupId': 'OG002'}, {'value': '0.0983', 'spread': '0.03734', 'groupId': 'OG003'}, {'value': '0.0505', 'spread': '0.02799', 'groupId': 'OG004'}, {'value': '0.0746', 'spread': '0.02523', 'groupId': 'OG005'}, {'value': '0.1902', 'spread': '0.06394', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 2 (n= 9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '-0.0148', 'spread': '0.03176', 'groupId': 'OG000'}, {'value': '-0.0205', 'spread': '0.00071', 'groupId': 'OG001'}, {'value': '-0.0670', 'spread': '0.08196', 'groupId': 'OG002'}, {'value': '-0.0408', 'spread': '0.03052', 'groupId': 'OG003'}, {'value': '-0.0212', 'spread': '0.01712', 'groupId': 'OG004'}, {'value': '-0.0298', 'spread': '0.01743', 'groupId': 'OG005'}, {'value': '-0.0307', 'spread': '0.08168', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 5 (n= 9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '-0.0352', 'spread': '0.03847', 'groupId': 'OG000'}, {'value': '-0.0050', 'spread': '0.02263', 'groupId': 'OG001'}, {'value': '-0.0972', 'spread': '0.11656', 'groupId': 'OG002'}, {'value': '-0.0753', 'spread': '0.02269', 'groupId': 'OG003'}, {'value': '-0.0435', 'spread': '0.02202', 'groupId': 'OG004'}, {'value': '-0.0596', 'spread': '0.03345', 'groupId': 'OG005'}, {'value': '-0.1078', 'spread': '0.05948', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 10 (n= 9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-0.0329', 'spread': '0.05656', 'groupId': 'OG000'}, {'value': '0.0015', 'spread': '0.00778', 'groupId': 'OG001'}, {'value': '-0.1002', 'spread': '0.11675', 'groupId': 'OG002'}, {'value': '-0.0903', 'spread': '0.00961', 'groupId': 'OG003'}, {'value': '-0.0467', 'spread': '0.02881', 'groupId': 'OG004'}, {'value': '-0.0618', 'spread': '0.01445', 'groupId': 'OG005'}, {'value': '-0.1838', 'spread': '0.04529', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 11 (n= 9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-0.0186', 'spread': '0.07315', 'groupId': 'OG000'}, {'value': '-0.0040', 'spread': '0.00990', 'groupId': 'OG001'}, {'value': '-0.1002', 'spread': '0.11675', 'groupId': 'OG002'}, {'value': '-0.0870', 'spread': '0.00819', 'groupId': 'OG003'}, {'value': '-0.0435', 'spread': '0.02849', 'groupId': 'OG004'}, {'value': '-0.0615', 'spread': '0.01330', 'groupId': 'OG005'}, {'value': '-0.1878', 'spread': '0.04136', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 28 (n= 9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '0.0496', 'spread': '0.18748', 'groupId': 'OG000'}, {'value': '0.0790', 'spread': '0.08910', 'groupId': 'OG001'}, {'value': '-0.0352', 'spread': '0.15033', 'groupId': 'OG002'}, {'value': '0.0023', 'spread': '0.06001', 'groupId': 'OG003'}, {'value': '0.0223', 'spread': '0.01556', 'groupId': 'OG004'}, {'value': '-0.0275', 'spread': '0.04086', 'groupId': 'OG005'}, {'value': '1.1255', 'spread': '1.63253', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, 5, 10, 11, 28', 'description': 'Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '1.0699', 'spread': '1.39179', 'groupId': 'OG000'}, {'value': '0.5694', 'spread': '1.11752', 'groupId': 'OG001'}, {'value': '0.3143', 'spread': '0.34167', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 2 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '-0.1096', 'spread': '0.25370', 'groupId': 'OG000'}, {'value': '-0.3408', 'spread': '0.86901', 'groupId': 'OG001'}, {'value': '-0.0189', 'spread': '0.14180', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 5 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '0.0204', 'spread': '0.51424', 'groupId': 'OG000'}, {'value': '-0.2413', 'spread': '1.45363', 'groupId': 'OG001'}, {'value': '-0.2119', 'spread': '0.27245', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 7 (n =9, 12, 7)', 'categories': [{'measurements': [{'value': '0.1958', 'spread': '0.85725', 'groupId': 'OG000'}, {'value': '-0.1573', 'spread': '1.90640', 'groupId': 'OG001'}, {'value': '-0.1983', 'spread': '0.31021', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 14 (n =9, 10, 6)', 'categories': [{'measurements': [{'value': '0.4118', 'spread': '1.19190', 'groupId': 'OG000'}, {'value': '-0.1910', 'spread': '0.65215', 'groupId': 'OG001'}, {'value': '-0.2582', 'spread': '0.33762', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 21 (n =9, 9, 5)', 'categories': [{'measurements': [{'value': '-0.1397', 'spread': '0.46958', 'groupId': 'OG000'}, {'value': '-0.3067', 'spread': '0.61035', 'groupId': 'OG001'}, {'value': '-0.2716', 'spread': '0.38954', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-0.4075', 'spread': '0.37814', 'groupId': 'OG000'}, {'value': '-0.3549', 'spread': '0.69576', 'groupId': 'OG001'}, {'value': '-0.2670', 'spread': '0.37674', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 29 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-0.6113', 'spread': '0.79373', 'groupId': 'OG000'}, {'value': '-0.3533', 'spread': '0.69589', 'groupId': 'OG001'}, {'value': '-0.2626', 'spread': '0.34387', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 35 (n =8, 6, 5)', 'categories': [{'measurements': [{'value': '-0.5945', 'spread': '0.78042', 'groupId': 'OG000'}, {'value': '-0.2533', 'spread': '0.79446', 'groupId': 'OG001'}, {'value': '0.7546', 'spread': '1.07215', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 56 (n =7, 6, 4)', 'categories': [{'measurements': [{'value': '-0.3407', 'spread': '0.45280', 'groupId': 'OG000'}, {'value': '-0.2662', 'spread': '0.78307', 'groupId': 'OG001'}, {'value': '0.2533', 'spread': '0.82107', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56', 'description': 'Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Baseline (n =13, 7, 6, 6, 6, 8, 8)', 'categories': [{'measurements': [{'value': '2.988', 'spread': '1.2090', 'groupId': 'OG000'}, {'value': '2.433', 'spread': '1.0574', 'groupId': 'OG001'}, {'value': '3.097', 'spread': '1.1903', 'groupId': 'OG002'}, {'value': '2.500', 'spread': '0.6782', 'groupId': 'OG003'}, {'value': '3.048', 'spread': '0.7552', 'groupId': 'OG004'}, {'value': '2.973', 'spread': '1.2374', 'groupId': 'OG005'}, {'value': '2.858', 'spread': '0.6901', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8)', 'categories': [{'measurements': [{'value': '0.096', 'spread': '0.7459', 'groupId': 'OG000'}, {'value': '0.340', 'spread': '0.6643', 'groupId': 'OG001'}, {'value': '0.377', 'spread': '0.7133', 'groupId': 'OG002'}, {'value': '0.285', 'spread': '0.3214', 'groupId': 'OG003'}, {'value': '0.240', 'spread': '0.7344', 'groupId': 'OG004'}, {'value': '-0.315', 'spread': '0.8594', 'groupId': 'OG005'}, {'value': '-0.760', 'spread': '0.5266', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8)', 'categories': [{'measurements': [{'value': '0.047', 'spread': '0.8048', 'groupId': 'OG000'}, {'value': '0.280', 'spread': '0.5187', 'groupId': 'OG001'}, {'value': '-0.162', 'spread': '1.1032', 'groupId': 'OG002'}, {'value': '-0.170', 'spread': '0.2265', 'groupId': 'OG003'}, {'value': '-0.170', 'spread': '0.6963', 'groupId': 'OG004'}, {'value': '0.296', 'spread': '0.3849', 'groupId': 'OG005'}, {'value': '0.654', 'spread': '0.6930', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8)', 'categories': [{'measurements': [{'value': '-0.245', 'spread': '0.7834', 'groupId': 'OG000'}, {'value': '0.196', 'spread': '0.1674', 'groupId': 'OG001'}, {'value': '0.017', 'spread': '1.1173', 'groupId': 'OG002'}, {'value': '-0.293', 'spread': '0.3100', 'groupId': 'OG003'}, {'value': '-0.058', 'spread': '0.9051', 'groupId': 'OG004'}, {'value': '-0.110', 'spread': '0.7910', 'groupId': 'OG005'}, {'value': '1.188', 'spread': '1.8134', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, 5, 8', 'unitOfMeasure': 'cells per millimeter cube (cells/mm^3)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '2.584', 'spread': '0.8858', 'groupId': 'OG000'}, {'value': '2.340', 'spread': '0.2970', 'groupId': 'OG001'}, {'value': '2.676', 'spread': '0.6726', 'groupId': 'OG002'}, {'value': '2.770', 'spread': '0.4907', 'groupId': 'OG003'}, {'value': '2.710', 'spread': '1.0372', 'groupId': 'OG004'}, {'value': '2.690', 'spread': '0.9337', 'groupId': 'OG005'}, {'value': '3.217', 'spread': '0.9677', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '0.099', 'spread': '0.4191', 'groupId': 'OG000'}, {'value': '0.060', 'spread': '0.0283', 'groupId': 'OG001'}, {'value': '-0.242', 'spread': '1.1533', 'groupId': 'OG002'}, {'value': '-0.215', 'spread': '0.6376', 'groupId': 'OG003'}, {'value': '-0.295', 'spread': '0.8000', 'groupId': 'OG004'}, {'value': '-0.980', 'spread': '0.3726', 'groupId': 'OG005'}, {'value': '-0.902', 'spread': '2.0680', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5)', 'categories': [{'measurements': [{'value': '0.239', 'spread': '0.5725', 'groupId': 'OG000'}, {'value': '0.635', 'spread': '1.1526', 'groupId': 'OG001'}, {'value': '-0.296', 'spread': '0.7032', 'groupId': 'OG002'}, {'value': '-0.178', 'spread': '0.5160', 'groupId': 'OG003'}, {'value': '-0.793', 'spread': '0.5720', 'groupId': 'OG004'}, {'value': '-0.913', 'spread': '0.4039', 'groupId': 'OG005'}, {'value': '-1.702', 'spread': '1.3292', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '0.156', 'spread': '0.5860', 'groupId': 'OG000'}, {'value': '0.635', 'spread': '1.0394', 'groupId': 'OG001'}, {'value': '-0.340', 'spread': '0.8602', 'groupId': 'OG002'}, {'value': '0.327', 'spread': '0.8228', 'groupId': 'OG003'}, {'value': '-1.012', 'spread': '0.5365', 'groupId': 'OG004'}, {'value': '-1.168', 'spread': '0.4197', 'groupId': 'OG005'}, {'value': '-2.125', 'spread': '1.2878', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '0.158', 'spread': '0.4996', 'groupId': 'OG000'}, {'value': '0.400', 'spread': '1.2021', 'groupId': 'OG001'}, {'value': '-0.382', 'spread': '0.8244', 'groupId': 'OG002'}, {'value': '0.260', 'spread': '0.7572', 'groupId': 'OG003'}, {'value': '-0.280', 'spread': '0.9159', 'groupId': 'OG004'}, {'value': '-0.248', 'spread': '0.3976', 'groupId': 'OG005'}, {'value': '-2.010', 'spread': '1.3075', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-0.020', 'spread': '0.5471', 'groupId': 'OG000'}, {'value': '0.385', 'spread': '0.8273', 'groupId': 'OG001'}, {'value': '-0.060', 'spread': '0.8663', 'groupId': 'OG002'}, {'value': '0.650', 'spread': '0.8543', 'groupId': 'OG003'}, {'value': '0.232', 'spread': '0.4395', 'groupId': 'OG004'}, {'value': '0.228', 'spread': '0.3377', 'groupId': 'OG005'}, {'value': '0.290', 'spread': '1.0943', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '0.030', 'spread': '0.4649', 'groupId': 'OG000'}, {'value': '0.130', 'spread': '0.4525', 'groupId': 'OG001'}, {'value': '-0.012', 'spread': '1.1401', 'groupId': 'OG002'}, {'value': '0.697', 'spread': '0.0839', 'groupId': 'OG003'}, {'value': '-0.055', 'spread': '0.4578', 'groupId': 'OG004'}, {'value': '0.050', 'spread': '0.6249', 'groupId': 'OG005'}, {'value': '0.298', 'spread': '0.3777', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 4, 8, 10, 11, 14, 28', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '4.109', 'spread': '1.4401', 'groupId': 'OG000'}, {'value': '3.640', 'spread': '1.4997', 'groupId': 'OG001'}, {'value': '3.909', 'spread': '1.1841', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 4 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '-0.402', 'spread': '0.9308', 'groupId': 'OG000'}, {'value': '0.006', 'spread': '1.1696', 'groupId': 'OG001'}, {'value': '0.153', 'spread': '0.7114', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 6 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '-0.209', 'spread': '1.2224', 'groupId': 'OG000'}, {'value': '-0.073', 'spread': '0.8229', 'groupId': 'OG001'}, {'value': '-0.303', 'spread': '0.6058', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 8 (n =9, 12, 7)', 'categories': [{'measurements': [{'value': '-0.473', 'spread': '0.6962', 'groupId': 'OG000'}, {'value': '0.013', 'spread': '1.2572', 'groupId': 'OG001'}, {'value': '-0.973', 'spread': '0.4394', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 10 (n =9, 10, 7)', 'categories': [{'measurements': [{'value': '-0.463', 'spread': '0.7834', 'groupId': 'OG000'}, {'value': '0.197', 'spread': '1.1099', 'groupId': 'OG001'}, {'value': '-1.299', 'spread': '0.6906', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 13 (n =9, 10, 6)', 'categories': [{'measurements': [{'value': '-0.654', 'spread': '0.7847', 'groupId': 'OG000'}, {'value': '-0.297', 'spread': '1.2264', 'groupId': 'OG001'}, {'value': '-1.538', 'spread': '0.9097', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 14 (n =9, 10, 6)', 'categories': [{'measurements': [{'value': '-0.247', 'spread': '0.9682', 'groupId': 'OG000'}, {'value': '-0.146', 'spread': '1.1226', 'groupId': 'OG001'}, {'value': '-1.465', 'spread': '0.9517', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 21 (n =9, 9, 5)', 'categories': [{'measurements': [{'value': '-0.762', 'spread': '0.7389', 'groupId': 'OG000'}, {'value': '-0.638', 'spread': '0.9404', 'groupId': 'OG001'}, {'value': '-1.410', 'spread': '1.2572', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-0.678', 'spread': '0.6416', 'groupId': 'OG000'}, {'value': '-0.890', 'spread': '0.9952', 'groupId': 'OG001'}, {'value': '-1.450', 'spread': '1.1195', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 35 (n =8, 6, 5)', 'categories': [{'measurements': [{'value': '-0.081', 'spread': '1.4496', 'groupId': 'OG000'}, {'value': '-0.777', 'spread': '1.1154', 'groupId': 'OG001'}, {'value': '-1.008', 'spread': '0.8082', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 42 (n =7, 6, 4)', 'categories': [{'measurements': [{'value': '-0.427', 'spread': '0.6004', 'groupId': 'OG000'}, {'value': '-0.677', 'spread': '1.1209', 'groupId': 'OG001'}, {'value': '-1.050', 'spread': '0.6868', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 56 (n =7, 6, 4)', 'categories': [{'measurements': [{'value': '-0.036', 'spread': '0.7864', 'groupId': 'OG000'}, {'value': '-0.533', 'spread': '1.3025', 'groupId': 'OG001'}, {'value': '-0.493', 'spread': '1.6373', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '8', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: SAD Cohort', 'description': 'Healthy participants received single tablet of placebo matched to PF-06700841, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG001', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG002', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 10 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 30 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 100 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 200 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}], 'classes': [{'title': 'Baseline (n =13, 7, 6, 6, 6, 8, 8)', 'categories': [{'measurements': [{'value': '1.23', 'spread': '0.470', 'groupId': 'OG000'}, {'value': '1.19', 'spread': '0.380', 'groupId': 'OG001'}, {'value': '0.98', 'spread': '0.279', 'groupId': 'OG002'}, {'value': '1.25', 'spread': '0.243', 'groupId': 'OG003'}, {'value': '1.25', 'spread': '0.327', 'groupId': 'OG004'}, {'value': '1.44', 'spread': '0.825', 'groupId': 'OG005'}, {'value': '1.20', 'spread': '0.524', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8)', 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.152', 'groupId': 'OG000'}, {'value': '-0.09', 'spread': '0.135', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.160', 'groupId': 'OG002'}, {'value': '-0.15', 'spread': '0.138', 'groupId': 'OG003'}, {'value': '0.02', 'spread': '0.256', 'groupId': 'OG004'}, {'value': '-0.14', 'spread': '0.177', 'groupId': 'OG005'}, {'value': '-0.16', 'spread': '0.177', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8)', 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.194', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.175', 'groupId': 'OG001'}, {'value': '-0.05', 'spread': '0.138', 'groupId': 'OG002'}, {'value': '-0.27', 'spread': '0.103', 'groupId': 'OG003'}, {'value': '0.02', 'spread': '0.409', 'groupId': 'OG004'}, {'value': '-0.23', 'spread': '0.459', 'groupId': 'OG005'}, {'value': '-0.15', 'spread': '0.193', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8)', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.234', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.114', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '0.242', 'groupId': 'OG002'}, {'value': '-0.15', 'spread': '0.226', 'groupId': 'OG003'}, {'value': '0.34', 'spread': '0.532', 'groupId': 'OG004'}, {'value': '-0.26', 'spread': '0.478', 'groupId': 'OG005'}, {'value': '-0.14', 'spread': '0.346', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, 5, 8', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: Once Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally once daily from Day 1 to Day 10. Treatment period 2 for MAD cohort was of 28 days.'}, {'id': 'OG001', 'title': 'Placebo: Twice Daily MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 tablet orally twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 10 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 10 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG003', 'title': 'PF-06700841: 30 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG004', 'title': 'PF-06700841: 100 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}, {'id': 'OG005', 'title': 'PF-06700841: 50 mg Twice Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 50 mg orally, twice daily from Day 1 to Day 10. Treatment period 3 for MAD cohort was of 28 days.'}, {'id': 'OG006', 'title': 'PF-06700841: 175 mg Once Daily MAD Cohort', 'description': 'Healthy participants received PF-06700841 tablet of 175 mg orally, once daily from Day 1 to Day 10. Treatment period 2 for MAD period was of 28 days.'}], 'classes': [{'title': 'Baseline (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '1.26', 'spread': '0.490', 'groupId': 'OG000'}, {'value': '0.85', 'spread': '0.212', 'groupId': 'OG001'}, {'value': '1.22', 'spread': '0.363', 'groupId': 'OG002'}, {'value': '1.03', 'spread': '0.350', 'groupId': 'OG003'}, {'value': '1.40', 'spread': '0.410', 'groupId': 'OG004'}, {'value': '2.26', 'spread': '0.550', 'groupId': 'OG005'}, {'value': '1.38', 'spread': '0.286', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6)', 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.212', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.071', 'groupId': 'OG001'}, {'value': '-0.10', 'spread': '0.071', 'groupId': 'OG002'}, {'value': '0.05', 'spread': '0.129', 'groupId': 'OG003'}, {'value': '-0.18', 'spread': '0.306', 'groupId': 'OG004'}, {'value': '-0.54', 'spread': '0.241', 'groupId': 'OG005'}, {'value': '-0.32', 'spread': '0.223', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5)', 'categories': [{'measurements': [{'value': '-0.11', 'spread': '0.285', 'groupId': 'OG000'}, {'value': '0.30', 'spread': '0.283', 'groupId': 'OG001'}, {'value': '-0.20', 'spread': '0.100', 'groupId': 'OG002'}, {'value': '-0.13', 'spread': '0.250', 'groupId': 'OG003'}, {'value': '-0.60', 'spread': '0.210', 'groupId': 'OG004'}, {'value': '-1.28', 'spread': '0.395', 'groupId': 'OG005'}, {'value': '-0.90', 'spread': '0.187', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-0.19', 'spread': '0.398', 'groupId': 'OG000'}, {'value': '0.20', 'spread': '0.283', 'groupId': 'OG001'}, {'value': '-0.24', 'spread': '0.089', 'groupId': 'OG002'}, {'value': '-0.07', 'spread': '0.231', 'groupId': 'OG003'}, {'value': '-0.70', 'spread': '0.352', 'groupId': 'OG004'}, {'value': '-1.48', 'spread': '0.403', 'groupId': 'OG005'}, {'value': '-0.93', 'spread': '0.206', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.343', 'groupId': 'OG000'}, {'value': '0.30', 'spread': '0.424', 'groupId': 'OG001'}, {'value': '-0.34', 'spread': '0.089', 'groupId': 'OG002'}, {'value': '-0.23', 'spread': '0.115', 'groupId': 'OG003'}, {'value': '-0.72', 'spread': '0.354', 'groupId': 'OG004'}, {'value': '-1.43', 'spread': '0.499', 'groupId': 'OG005'}, {'value': '-0.93', 'spread': '0.330', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.393', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '0.495', 'groupId': 'OG001'}, {'value': '-0.22', 'spread': '0.110', 'groupId': 'OG002'}, {'value': '0.03', 'spread': '0.058', 'groupId': 'OG003'}, {'value': '-0.60', 'spread': '0.297', 'groupId': 'OG004'}, {'value': '-1.10', 'spread': '0.408', 'groupId': 'OG005'}, {'value': '-0.90', 'spread': '0.183', 'groupId': 'OG006'}]}]}, {'title': 'Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)', 'categories': [{'measurements': [{'value': '0.11', 'spread': '0.431', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.212', 'groupId': 'OG001'}, {'value': '0.22', 'spread': '0.277', 'groupId': 'OG002'}, {'value': '0.30', 'spread': '0.346', 'groupId': 'OG003'}, {'value': '0.65', 'spread': '0.619', 'groupId': 'OG004'}, {'value': '0.18', 'spread': '0.189', 'groupId': 'OG005'}, {'value': '0.33', 'spread': '0.479', 'groupId': 'OG006'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 4, 8, 10, 11, 14, 28', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}, {'type': 'SECONDARY', 'title': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG001', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'OG002', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}], 'classes': [{'title': 'Baseline (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '1.49', 'spread': '0.355', 'groupId': 'OG000'}, {'value': '1.45', 'spread': '0.285', 'groupId': 'OG001'}, {'value': '1.31', 'spread': '0.393', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 4 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.300', 'groupId': 'OG000'}, {'value': '-0.09', 'spread': '0.207', 'groupId': 'OG001'}, {'value': '-0.13', 'spread': '0.281', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 6 (n =9, 14, 7)', 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.392', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '0.250', 'groupId': 'OG001'}, {'value': '-0.27', 'spread': '0.373', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 8 (n =9, 12, 7)', 'categories': [{'measurements': [{'value': '-0.20', 'spread': '0.430', 'groupId': 'OG000'}, {'value': '-0.21', 'spread': '0.243', 'groupId': 'OG001'}, {'value': '-0.59', 'spread': '0.353', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 10 (n =9, 10, 7)', 'categories': [{'measurements': [{'value': '-0.21', 'spread': '0.355', 'groupId': 'OG000'}, {'value': '-0.35', 'spread': '0.295', 'groupId': 'OG001'}, {'value': '-0.70', 'spread': '0.361', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 13 (n =9, 10, 6)', 'categories': [{'measurements': [{'value': '-0.20', 'spread': '0.354', 'groupId': 'OG000'}, {'value': '-0.41', 'spread': '0.373', 'groupId': 'OG001'}, {'value': '-0.75', 'spread': '0.459', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 14 (n =9, 10, 6)', 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.371', 'groupId': 'OG000'}, {'value': '-0.34', 'spread': '0.392', 'groupId': 'OG001'}, {'value': '-0.82', 'spread': '0.462', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 21 (n =9, 9, 5)', 'categories': [{'measurements': [{'value': '-0.22', 'spread': '0.393', 'groupId': 'OG000'}, {'value': '-0.27', 'spread': '0.430', 'groupId': 'OG001'}, {'value': '-0.66', 'spread': '0.270', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 28 (n =8, 7, 5)', 'categories': [{'measurements': [{'value': '-0.24', 'spread': '0.487', 'groupId': 'OG000'}, {'value': '-0.36', 'spread': '0.264', 'groupId': 'OG001'}, {'value': '-0.60', 'spread': '0.255', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 35 (n =8, 6, 5)', 'categories': [{'measurements': [{'value': '0.26', 'spread': '0.498', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.163', 'groupId': 'OG001'}, {'value': '0.22', 'spread': '0.228', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 42 (n =7, 6, 4)', 'categories': [{'measurements': [{'value': '0.46', 'spread': '0.431', 'groupId': 'OG000'}, {'value': '0.33', 'spread': '0.427', 'groupId': 'OG001'}, {'value': '1.35', 'spread': '0.551', 'groupId': 'OG002'}]}]}, {'title': 'Change at Day 56 (n =7, 6, 4', 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.335', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.250', 'groupId': 'OG001'}, {'value': '0.50', 'spread': '0.183', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PD analysis set included all randomized and treated participants who had at least 1 of the PD parameters of interest. Here, 'n' signifies those participants who were evaluable at specified time points for each arm, respectively."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'FG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'FG002', 'title': 'PF--06700841: 10 mg SAD Cohort Then MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 10 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).'}, {'id': 'FG003', 'title': 'PF-06700841: 30 mg SAD Cohort Then MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 30 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).'}, {'id': 'FG004', 'title': 'PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 100 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days, then PF-06700841 tablet 50 mg orally, twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).'}, {'id': 'FG005', 'title': 'PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 175 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).'}, {'id': 'FG006', 'title': 'Placebo: SAD Cohort Then MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 single tablet orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then placebo matched to PF-06700841 tablet once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days followed by placebo matched to PF-06700841 tablet twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).'}, {'id': 'FG007', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'FG008', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'FG009', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'FG010', 'title': 'PF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution Fasted', 'description': 'Participants received PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 2 (9 days) followed by second washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.'}, {'id': 'FG011', 'title': 'PF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet Fed', 'description': 'Participants received PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.'}, {'id': 'FG012', 'title': 'PF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet Fasted', 'description': 'Participants received PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.'}, {'id': 'FG013', 'title': 'PF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet Fed', 'description': 'Participants received PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.'}, {'id': 'FG014', 'title': 'PF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet Fasted', 'description': 'Participants received PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.'}, {'id': 'FG015', 'title': 'PF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted', 'description': 'Participants received PF-06700841 100 mg tablet under fed condition at Day 1 of treatment period 1 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg tablet under fasted condition at Day 1 of treatment period 2 (9 days) followed by washout period (5 days) followed by PF-06700841 100 mg oral solution/suspension under fasted condition at Day 1 of treatment period 3 (9 days) in food effect cohorts.'}], 'periods': [{'title': 'HP Period 1', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '13'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '5'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '12'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}]}, {'title': 'HP Washout 1', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '5'}, {'groupId': 'FG004', 'numSubjects': '8'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '12'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '9'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}]}, {'title': 'HP MAD, Psoriasis MD, HP Fasted/Fed', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '9'}, {'groupId': 'FG007', 'numSubjects': '9'}, {'groupId': 'FG008', 'numSubjects': '14'}, {'groupId': 'FG009', 'numSubjects': '7'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '9'}, {'groupId': 'FG007', 'numSubjects': '7'}, {'groupId': 'FG008', 'numSubjects': '6'}, {'groupId': 'FG009', 'numSubjects': '4'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '8'}, {'groupId': 'FG009', 'numSubjects': '3'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '6'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}, {'type': 'Non-Compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '1'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '1'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}]}, {'title': 'HP Washout 2', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '9'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '5'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '7'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '7'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}]}, {'title': 'HP MAD and Fasted/Fed', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '5'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'Study conducted in 7 Healthy Participant (HP) cohorts: 6 cohorts included Single Ascending Dose (SAD), 4 which continued into Multiple Ascending Dose (MAD) with washout, and a final cohort was tested for food effect (fasted/fed) with washout. 1 multiple dose (MD) cohort in Psoriasis subjects received drug at 2 different dose levels or placebo.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}, {'value': '13', 'groupId': 'BG006'}, {'value': '9', 'groupId': 'BG007'}, {'value': '14', 'groupId': 'BG008'}, {'value': '7', 'groupId': 'BG009'}, {'value': '12', 'groupId': 'BG010'}, {'value': '96', 'groupId': 'BG011'}]}], 'groups': [{'id': 'BG000', 'title': 'PF--06700841: 1 Milligram (mg) SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 1 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'BG001', 'title': 'PF--06700841: 3 mg SAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 3 mg, orally on Day 1. Treatment period 1 for SAD cohort was of 8 days.'}, {'id': 'BG002', 'title': 'PF--06700841: 10 mg SAD Cohort Then MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 10 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 10 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).'}, {'id': 'BG003', 'title': 'PF-06700841: 30 mg SAD Cohort Then MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 30 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 30 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).'}, {'id': 'BG004', 'title': 'PF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 100 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 100 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days, then PF-06700841 tablet 50 mg orally, twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).'}, {'id': 'BG005', 'title': 'PF--06700841: 200 mg SAD Cohort, 175 mg MAD Cohort', 'description': 'Healthy participants received PF-06700841 single tablet of 200 mg, orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then PF-06700841 tablet 175 mg orally, once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days).'}, {'id': 'BG006', 'title': 'Placebo: SAD Cohort Then MAD Cohort', 'description': 'Healthy participants received placebo matched to PF-06700841 single tablet orally on Day 1 in the treatment period 1 for SAD cohort (8 days) followed by washout period of at least 7 days, then placebo matched to PF-06700841 tablet once daily from Day 1 to Day 10 in the treatment period 2 for MAD cohort (28 days) followed by washout period of at least 7 days followed by placebo matched to PF-06700841 tablet twice daily from Day 1 to Day 10 in the treatment period 3 for MAD cohort (28 days).'}, {'id': 'BG007', 'title': 'Placebo: MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received placebo matched to PF-06700841 tablet orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'BG008', 'title': 'PF-06700841: 30 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 30 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'BG009', 'title': 'PF-06700841: 100 mg MAD Psoriasis Cohort', 'description': 'Participants with Psoriasis received PF-06700841 tablet of 100 mg orally, once daily from Day 1 to Day 28. Treatment period 2 for MAD Psoriasis cohort was of 56 days.'}, {'id': 'BG010', 'title': 'PF-06700841: 100 mg Food Effect Cohort', 'description': 'All participants who received either PF-06700841 100 mg tablet under fasted condition or PF-06700841 100 mg tablet under fed condition or PF-06700841 100 mg oral solution/suspension under fasted condition in either 1 of the 3 treatment period in any 1 of the 6 treatment sequences in food effects cohort of the study.'}, {'id': 'BG011', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': '18-44 Years', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '11', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '5', 'groupId': 'BG009'}, {'value': '5', 'groupId': 'BG010'}, {'value': '55', 'groupId': 'BG011'}]}]}, {'title': '45-64 Years', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}, {'value': '8', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '7', 'groupId': 'BG010'}, {'value': '41', 'groupId': 'BG011'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Gender', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '6', 'groupId': 'BG011'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '8', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}, {'value': '8', 'groupId': 'BG007'}, {'value': '12', 'groupId': 'BG008'}, {'value': '7', 'groupId': 'BG009'}, {'value': '11', 'groupId': 'BG010'}, {'value': '90', 'groupId': 'BG011'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 96}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-01', 'completionDateStruct': {'date': '2016-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-01-13', 'studyFirstSubmitDate': '2014-11-18', 'resultsFirstSubmitDate': '2017-01-13', 'studyFirstSubmitQcDate': '2014-12-04', 'lastUpdatePostDateStruct': {'date': '2017-03-08', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-01-13', 'studyFirstPostDateStruct': {'date': '2014-12-08', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2017-03-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28'}, {'measure': 'Number of Participants With Change From Baseline in Physical Examinations', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': 'Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.'}, {'measure': 'Number of Adverse Events (AEs) According to Severity', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': "An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function."}, {'measure': 'Number of Participants With Laboratory Abnormalities', 'timeFrame': 'SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37', 'description': 'Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(\\<) 0.8\\*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: \\<0.9\\*LLN,\\>1.1\\*upper limit of normal (ULN); platelets: \\<0.5\\*LLN,\\>1.75\\*ULN, white blood cell count: \\<0.6\\*LLN, \\>1.5\\*ULN; lymphocytes, total neutrophils: \\<0.8\\*LLN, \\>1.2\\*ULN; eosinophils, basophils, monocytes: \\>1.2\\*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: \\>1.1\\*ULN; liver function: bilirubin: \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \\>3.0\\*ULN; protein, albumin: \\<0.8\\*LLN\\>\\</0\\>1.2\\*ULN; renal function:blood urea nitrogen,creatinine: \\>1.3\\*ULN; uric acid: \\>1.2\\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \\<0.9\\*LLN,\\>1.1\\*ULN; urinalysis: pH\\<4.5, \\>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \\<0.6\\*LLN,\\>1.5\\*ULN)'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1', 'timeFrame': 'Baseline, 24 hours post-dose on Day 1', 'description': 'Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.'}, {'measure': 'Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10', 'timeFrame': 'Baseline, 16 hours post-dose on Day 10', 'description': 'Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28', 'timeFrame': 'Baseline, 16 hours post-dose on Day 28', 'description': 'Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.'}, {'measure': 'Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841', 'timeFrame': 'Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).'}, {'measure': 'Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1', 'description': 'Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).'}, {'measure': 'Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1'}], 'secondaryOutcomes': [{'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841', 'timeFrame': 'SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841', 'timeFrame': 'SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28'}, {'measure': 'Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841', 'timeFrame': 'Pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).'}, {'measure': 'Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841', 'timeFrame': 'MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28', 'description': 'Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841', 'timeFrame': 'SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28', 'description': 'Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841', 'timeFrame': 'pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841', 'timeFrame': 'Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1', 'description': 'Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841', 'timeFrame': 'pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10', 'description': 'Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841', 'timeFrame': 'SAD: pre--dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre--dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28', 'description': 'Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841', 'timeFrame': 'SAD: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28', 'description': 'MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841', 'timeFrame': 'SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841', 'timeFrame': 'SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28', 'description': 'Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.'}, {'measure': 'Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841', 'timeFrame': 'MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28', 'description': 'PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC\\[tau\\]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)', 'timeFrame': '0-24 hour on Day 10', 'description': 'Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)', 'timeFrame': '0-24 hours on Day 10', 'description': 'Aetau% was calculated as: 100\\*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Renal Clearance', 'timeFrame': '0-24 hours on Day 10', 'description': 'Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline', 'timeFrame': 'Baseline', 'description': 'Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28', 'timeFrame': 'Baseline, Day 2, 5, 10, 11, 28', 'description': 'Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56', 'timeFrame': 'Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56', 'description': 'Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline', 'timeFrame': 'Baseline', 'description': 'Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28', 'timeFrame': 'Baseline, Day 2, 5, 10, 11, 28', 'description': 'Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56', 'timeFrame': 'Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56', 'description': 'Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8', 'timeFrame': 'Baseline, Day 2, 5, 8'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28', 'timeFrame': 'Baseline, Day 4, 8, 10, 11, 14, 28'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56', 'timeFrame': 'Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56'}, {'measure': 'Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8', 'timeFrame': 'Baseline, Day 2, 5, 8'}, {'measure': 'Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28', 'timeFrame': 'Baseline, Day 4, 8, 10, 11, 14, 28'}, {'measure': 'Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56', 'timeFrame': 'Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Plaque Psoriasis']}, 'referencesModule': {'references': [{'pmid': '36045513', 'type': 'DERIVED', 'citation': 'Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1447-1456. doi: 10.1002/cpdd.1163. Epub 2022 Aug 31.'}, {'pmid': '31972249', 'type': 'DERIVED', 'citation': 'Page KM, Suarez-Farinas M, Suprun M, Zhang W, Garcet S, Fuentes-Duculan J, Li X, Scaramozza M, Kieras E, Banfield C, Clark JD, Fensome A, Krueger JG, Peeva E. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. J Invest Dermatol. 2020 Aug;140(8):1546-1555.e4. doi: 10.1016/j.jid.2019.11.027. Epub 2020 Jan 21.'}, {'pmid': '29266308', 'type': 'DERIVED', 'citation': 'Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434-447. doi: 10.1002/jcph.1046. Epub 2017 Dec 21.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931001&StudyName=A%20Phase%201%2C%20Within%20Cohort%2C%20Randomized%2C%20Double%20Blind%2C%20Third-party%20Open%2C%20Placebo-controlled%2C%20Single-%20And%20Multiple%20Dose%20Escalation%2C%20Parallel%20Group%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Pf-06700841%20In%20Healthy%20Subjects%20And%20Subjects%20With%20Plaque%20Psoriasis%20And%20Bioavailability%20Of%20A%20Tablet%20Formulation%20Relative%20To%20Suspension%20Formulation%20And%20The%20Effect%20Of%20Food%20On%20A%20Tablet%20Formulation%20Of%20Pf-06700841', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\nKey Inclusion Criteria for Healthy Subject Cohorts:\n\n* Healthy male subjects and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive\n* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)\n\nKey Inclusion Criteria for Psoriasis Subject Cohorts:\n\n* Male subjects and/or female subjects of non-childbearing potential with a diagnosis of plaque psoriasis who are between the ages of 18 and 65 years, inclusive\n* Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose\n\nExclusion Criteria:\n\nKey Exclusion Criteria for Healthy Subject Cohorts:\n\n* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)\n* Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product\n\nKey Exclusion Criteria for Psoriasis Subject Cohorts:\n\n* Currently have non plaque forms of psoriasis, (eg, erythrodermic, guttate, or pustular psoriasis).\n* Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium\n* Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product'}, 'identificationModule': {'nctId': 'NCT02310750', 'briefTitle': 'A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841', 'orgStudyIdInfo': {'id': 'B7931001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'PF-06700841 Oral Solution/Suspension', 'interventionNames': ['Drug: PF-06700841 oral solution/suspension']}, {'type': 'EXPERIMENTAL', 'label': 'PF-06700841 Tablet', 'interventionNames': ['Drug: PF-06700841 tablet']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'PF-06700841 oral solution/suspension', 'type': 'DRUG', 'description': 'Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)', 'armGroupLabels': ['PF-06700841 Oral Solution/Suspension']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Matching placebo given during the single ascending and multiple dose periods', 'armGroupLabels': ['Placebo']}, {'name': 'PF-06700841 tablet', 'type': 'DRUG', 'description': 'PF-06700841 tablet formulation administered during the bioavailability / food effect investigation', 'armGroupLabels': ['PF-06700841 Tablet']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92801', 'city': 'Anaheim', 'state': 'California', 'country': 'United States', 'facility': 'Anaheim Clinical Trials, LLC', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}